TRKA (G595R/G667S)
Sign in to save this workspaceNTRK1 · Variant type: compound · HGVS: p.G595R;p.G667S
Components
p.G595Rp.G667S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 100.0% | 0.0% | 84.21 |
| 2 | Ponatinib | 98.8% | 1.2% | 78.23 |
| 3 | Darovasertib | 92.2% | 7.8% | 96.99 |
| 4 | Cabozantinib | 88.0% | 12.0% | 92.73 |
| 5 | Entrectinib | 83.0% | 17.0% | 93.69 |
| 6 | Pralsetinib | 77.4% | 22.6% | 93.43 |
| 7 | Defactinib | 64.0% | 36.0% | 92.68 |
| 8 | Nintedanib | 39.4% | 60.6% | 90.23 |
| 9 | Sunitinib | 24.3% | 75.7% | 91.73 |
| 10 | Tenalisib | 21.4% | 78.6% | 97.98 |
| 11 | Asciminib | 17.4% | 82.6% | 100.00 |
| 12 | Fedratinib | 16.1% | 83.9% | 96.21 |
| 13 | Gilteritinib | 15.1% | 84.9% | 88.97 |
| 14 | Pacritinib | 12.4% | 87.6% | 88.64 |
| 15 | Everolimus | 11.0% | 89.0% | 100.00 |
| 16 | Axitinib | 10.3% | 89.7% | 93.23 |
| 17 | Bosutinib | 8.8% | 91.2% | 87.22 |
| 18 | Deucravacitinib | 8.7% | 91.3% | 98.99 |
| 19 | Pirtobrutinib | 8.1% | 91.9% | 99.49 |
| 20 | Erdafitinib | 8.0% | 92.0% | 95.71 |
| 21 | Ripretinib | 7.7% | 92.3% | 92.95 |
| 22 | Futibatinib | 7.7% | 92.3% | 98.48 |
| 23 | Ruxolitinib | 7.7% | 92.3% | 98.25 |
| 24 | Afatinib | 7.4% | 92.6% | 98.50 |
| 25 | Ribociclib | 7.3% | 92.7% | 99.25 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 100.0% | 98.9% | +1.1% |
| Ponatinib | 98.8% | 98.4% | +0.4% |
| Darovasertib | 92.2% | — | — |
| Cabozantinib | 88.0% | 93.6% | -5.5% |
| Entrectinib | 83.0% | 99.0% | -16.0% |
| Pralsetinib | 77.4% | 98.7% | -21.2% |
| Defactinib | 64.0% | 80.3% | -16.3% |
| Nintedanib | 39.4% | 93.8% | -54.4% |
| Sunitinib | 24.3% | 82.8% | -58.4% |
| Tenalisib | 21.4% | 59.0% | -37.6% |
| Asciminib | 17.4% | — | — |
| Fedratinib | 16.1% | 56.2% | -40.1% |
| Gilteritinib | 15.1% | 92.6% | -77.5% |
| Pacritinib | 12.4% | 89.4% | -77.1% |
| Everolimus | 11.0% | — | — |
| Axitinib | 10.3% | — | — |
| Bosutinib | 8.8% | 67.0% | -58.2% |
| Deucravacitinib | 8.7% | — | — |
| Pirtobrutinib | 8.1% | — | — |
| Erdafitinib | 8.0% | — | — |
| Ripretinib | 7.7% | 93.6% | -85.9% |
| Futibatinib | 7.7% | — | — |
| Ruxolitinib | 7.7% | — | — |
| Afatinib | 7.4% | — | — |
| Ribociclib | 7.3% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.7ms